Artificial Intelligence (AI) in Drugs and Pharmaceuticals

被引:18
|
作者
Sahu, Adarsh [1 ]
Mishra, Jyotika [1 ]
Kushwaha, Namrata [2 ]
机构
[1] Dr Hari Singh Gour Vishwavidyalaya, Dept Pharmaceut Sci, Sagar, MP, India
[2] Sri Aurobindo Inst Pharm, Indore, MP, India
关键词
Deep learning; machine learning; artificial neural network; drug design; drug discovery; pharmaceuticals; VIRTUAL SCREENING STRATEGIES; PROTEIN-PROTEIN INTERFACES; DE-NOVO DESIGN; MOLECULAR-PROPERTIES; INTERACTION NETWORKS; SECONDARY STRUCTURE; SCORING FUNCTION; NEURAL-NETWORKS; HEALTH-CARE; PREDICTION;
D O I
10.2174/1386207325666211207153943
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The advancement of computing and technology has invaded all the dimensions of science. Artificial intelligence (AI) is one core branch of Computer Science, which has percolated to all the arenas of science and technology, from core engineering to medicines. Thus, AI has found its way for application in the field of medicinal chemistry and heath care. The conventional methods of drug design have been replaced by computer-aided designs of drugs in recent times. AI is being used extensively to improve the design techniques and required time of the drugs. Additionally, the target proteins can be conveniently identified using AI, which enhances the success rate of the designed drug. The AI technology is used in each step of the drug designing procedure, which decreases the health hazards related to preclinical trials and also reduces the cost substantially. The AI is an effective tool for data mining based on the huge pharmacological data and machine learning process. Hence, AI has been used in de novo drug design, activity scoring, virtual screening and in silico evaluation in the properties (absorption, distribution, metabolism, excretion and toxicity) of a drug molecule. Various pharmaceutical companies have teamed up with AI companies for faster progress in the field of drug development, along with the healthcare system. The review covers various aspects of AI (Machine learning, Deep learning, Artificial neural networks) in drug design. It also provides a brief overview of the recent progress by the pharmaceutical companies in drug discovery by associating with different AI companies.
引用
收藏
页码:1818 / 1837
页数:20
相关论文
共 50 条
  • [31] Editorial - Artificial Intelligence (AI) for Business
    Selvam, Murugesan
    [J]. SMART-JOURNAL OF BUSINESS MANAGEMENT STUDIES, 2021, 17 (01) : VIII - IX
  • [32] Expectations for Artificial Intelligence (AI) in Psychiatry
    Monteith, Scott
    Glenn, Tasha
    Geddes, John
    Whybrow, Peter C.
    Achtyes, Eric
    Bauer, Michael
    [J]. CURRENT PSYCHIATRY REPORTS, 2022, 24 (11) : 709 - 721
  • [33] Artificial intelligence (AI) ethics in business
    Sison, Alejo
    Ferrero, Ignacio
    Garcia Ruiz, Pablo
    Kim, Tae Wan
    [J]. FRONTIERS IN PSYCHOLOGY, 2023, 14
  • [34] Artificial intelligence (AI) in blended learning
    Garner, Brian J.
    Tsui, Eric
    Lukose, Dickson
    [J]. KNOWLEDGE-BASED SYSTEMS, 2009, 22 (04) : 247 - 248
  • [35] ARTIFICIAL INTELLIGENCE AI protein database
    Megget, Katrina
    [J]. CHEMISTRY & INDUSTRY, 2021, 85 (09) : 10 - 10
  • [36] Artificial Intelligence (AI) in Agriculture Introduction
    Liu, Simon Y.
    [J]. IT PROFESSIONAL, 2020, 22 (03) : 14 - 15
  • [37] Artificial Intelligence (AI) in pediatric endocrinology
    Winkelman, Jeremy
    Nguyen, Diep
    vanSonnenberg, Eric
    Kirk, Alison
    Lieberman, Steven
    [J]. JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2023, 36 (10): : 903 - 908
  • [38] AI 2000: A Decade of Artificial Intelligence
    Shao, Zhou
    Shen, Zhenting
    Yuan, Sha
    Tang, Jie
    Wang, Yongli
    Wu, Lili
    Zheng, Wenjiang
    [J]. PROCEEDINGS OF THE 12TH ACM CONFERENCE ON WEB SCIENCE, WEBSCI 2020, 2020, : 345 - 354
  • [39] Musicology in the Era of Artificial Intelligence (AI)
    Ros-Fabregas, Emilio
    [J]. ANUARIO MUSICAL, 2023, (78) : 7 - 12
  • [40] AI (Artificial Intelligence) and Hypertension Research
    Mueller, Franco B.
    [J]. CURRENT HYPERTENSION REPORTS, 2020, 22 (09)